Story
Praxis Stock Surges After Positive FDA Updates on Two Neurological Drugs

Shares of Praxis Precision Medicines (PRAX) surged more than 9% in pre-market trading Tuesday following a corporate update that significantly de-risked the regulatory pathways for two of its leading drug candidates. The company announced positive mid-cycle reviews from the U.S. Food and Drug Administration for both programs, coupled with a strong financial position that alleviates near-term funding concerns.
Key Regulatory Milestones
The FDA completed its mid-cycle reviews for both ulixacaltamide, a treatment candidate for essential tremor, and relutrigine, a therapy for rare developmental and epileptic encephalopathies. According to the company, regulators found no major safety or efficacy concerns for either program and opted not to convene an advisory committee, a development investors view as a positive signal ahead of final decisions.
The PDUFA target action date for relutrigine is December 27, 2026, and the date for ulixacaltamide is January 29, 2027.
Adding to the positive regulatory news, Praxis reported that FDA Bioresearch Monitoring inspections related to both drug applications were completed with zero Form FDA 483 observations. A clean inspection without any findings is a strong indicator of sound data integrity and smooth regulatory execution.
Financial Strength and Pipeline Progress
AdPraxis also strengthened investor confidence by reporting a robust balance sheet. The company held approximately $1.4 billion in cash and investments as of June 30, 2026.
This cash position provides a financial runway into 2028, removing the risk of a near-term capital raise as the company awaits the FDA's approval decisions. Separately, Praxis disclosed it had received a third Breakthrough Therapy Designation for another pipeline asset, elsunersen, following positive trial results.
Market Reaction
The stock's 9.3% pre-market jump was a direct reaction to the company-specific news, standing in contrast to the broader market, where the Nasdaq Composite was slightly lower and the S&P 500 was flat. The move pushed Praxis shares toward the upper end of their 52-week range, reflecting strong investor optimism about the company's late-stage assets.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.